Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom.
Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):998-1002. doi: 10.1073/pnas.1616903114. Epub 2017 Jan 17.
Many promising vaccine candidates from pathogenic viruses, bacteria, and parasites are unstable and cannot be produced cheaply for clinical use. For instance, Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is essential for erythrocyte invasion, is highly conserved among field isolates, and elicits antibodies that neutralize in vitro and protect in an animal model, making it a leading malaria vaccine candidate. However, functional RH5 is only expressible in eukaryotic systems and exhibits moderate temperature tolerance, limiting its usefulness in hot and low-income countries where malaria prevails. Current approaches to immunogen stabilization involve iterative application of rational or semirational design, random mutagenesis, and biochemical characterization. Typically, each round of optimization yields minor improvement in stability, and multiple rounds are required. In contrast, we developed a one-step design strategy using phylogenetic analysis and Rosetta atomistic calculations to design PfRH5 variants with improved packing and surface polarity. To demonstrate the robustness of this approach, we tested three PfRH5 designs, all of which showed improved stability relative to wild type. The best, bearing 18 mutations relative to PfRH5, expressed in a folded form in bacteria at >1 mg of protein per L of culture, and had 10-15 °C higher thermal tolerance than wild type, while also retaining ligand binding and immunogenic properties indistinguishable from wild type, proving its value as an immunogen for a future generation of vaccines against the malaria blood stage. We envision that this efficient computational stability design methodology will also be used to enhance the biophysical properties of other recalcitrant vaccine candidates from emerging pathogens.
许多来自致病性病毒、细菌和寄生虫的有前途的疫苗候选物不稳定,无法廉价生产用于临床应用。例如,疟原虫红细胞结合蛋白同源物 5(PfRH5)对于红细胞入侵是必不可少的,在野外分离株中高度保守,并产生中和体外和在动物模型中保护的抗体,使其成为领先的疟疾疫苗候选物。然而,功能性 RH5 仅在真核系统中可表达,并且表现出中等的温度耐受性,限制了其在疟疾流行的炎热和低收入国家中的用途。目前的免疫原稳定化方法涉及迭代应用合理或半合理设计、随机诱变和生化特性分析。通常,每一轮优化都会使稳定性略有提高,需要多轮优化。相比之下,我们使用系统发育分析和罗塞塔原子计算开发了一种一步设计策略,用于设计具有改进包装和表面极性的 PfRH5 变体。为了证明这种方法的稳健性,我们测试了三个 PfRH5 设计,它们都表现出比野生型更高的稳定性。最好的设计与 PfRH5 相比有 18 个突变,在细菌中以每升培养物超过 1 毫克的蛋白表达折叠形式,并且比野生型高出 10-15°C 的热稳定性,同时还保留了与野生型不可区分的配体结合和免疫原性,证明了它作为未来一代疟疾血阶段疫苗的免疫原的价值。我们设想这种高效的计算稳定性设计方法也将用于增强来自新兴病原体的其他顽固疫苗候选物的生物物理特性。